Age-dependent effect of β-blockers in preventing vasovagal syncope

Circulation: Arrhythmia and Electrophysiology

Volumn 5, Issue 5, 2012, Pages 920-926

  Sheldon, Robert S ^a   Morillo, Carlos A ^b   Klingenheben, Thomas ^c   Krahn, Andrew D ^d   Sheldon, Aaron ^a   Rose, M Sarah ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c GOETHE UNIVERSITY   (Germany)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

blockers; Aging; Clinical trials; Syncope

Indexed keywords

ATENOLOL; METOPROLOL; NADOLOL; PINDOLOL; PROPRANOLOL; TIMOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADULT; AGE DISTRIBUTION; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FAINTNESS; FEMALE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; AGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; MIDDLE AGED; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TILT TABLE TEST; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGE FACTORS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METOPROLOL; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE; SYNCOPE, VASOVAGAL; TILT-TABLE TEST; TREATMENT OUTCOME;

EID: 84870515907     PISSN: 19413149     EISSN: 19413084     Source Type: Journal    
DOI: 10.1161/CIRCEP.112.974386     Document Type: Article

References (44)

1. Kuriachan V, Sheldon RS, Platonov M. Evidence-based treatment for vasovagal syncope. Heart Rhythm. 2008;5:1609-1614.
2. Almquist A, Goldenberg IF, Milstein S, Chen MY, Chen XC, Hansen R, Gornick CC, Benditt DG. Provocation of bradycardia and hypotension by isoproterenol and upright posture in patients with unexplained syncope. N Engl J Med. 1989;320:346-351.
3. Cox MM, Perlman BA, Mayor MR, Silberstein TA, Levin E, Pringle L, Castellanos A, Myerburg RJ. Acute and long-term beta-adrenergic blockade for patients with neurocardiogenic syncope. J Am Coll Cardiol. 1995;26:1293-1298.
4. Mahanonda N, Bhuripanyo K, Kangkagate C, Wansanit K, Kulchot B, Nademanee K, Chaithiraphan S. Randomized double-blind, placebo-controlled trial of oral atenolol in patients with unexplained syncope and positive upright tilt table test results. Am Heart J. 1995;130:1250-1253.
5. Alegria JR, Gersh BJ, Scott CG, Hodge DO, Hammill SC, Shen WK. Comparison of frequency of recurrent syncope after beta-blocker therapy versus conservative management for patients with vasovagal syncope. Am J Cardiol. 2003;92:82-84.
6. Sheldon R, Rose S, Flanagan P, Koshman ML, Killam S. Effect of beta blockers on the time to first syncope recurrence in patients after a positive isoproterenol tilt table test. Am J Cardiol. 1996;78:536-539.
7. Flevari P, Livanis EG, Theodorakis GN, Zarvalis E, Mesiskli T, Kremastinos DT. Vasovagal syncope: a prospective, randomized, crossover evaluation of the effect of propranolol, nadolol and placebo on syncope recurrence and patients' well-being. J Am Coll Cardiol. 2002;40:499-504.
8. Madrid AH, Ortega J, Rebollo JG, Manzano JG, Segovia JG, Sánchez A, Peña G, Moro C. Lack of efficacy of atenolol for the prevention of neurally mediated syncope in a highly symptomatic population: a prospective, double-blind, randomized and placebo-controlled study. J Am Coll Cardiol. 2001;37:554-559.
9. Sheldon R, Connolly S, Rose S, Klingenheben T, Krahn A, Morillo C, Talajic M, Ku T, Fouad-Tarazi F, Ritchie D, Koshman ML; POST Investigators. Prevention of Syncope Trial (POST): a randomized, placebo-controlled study of metoprolol in the prevention of vasovagal syncope. Circulation. 2006;113:1164-1170.
10. Ventura R, Maas R, Zeidler D, Schoder V, Nienaber CA, Schuchert A, Meinertz T. A randomized and controlled pilot trial of beta-blockers for the treatment of recurrent syncope in patients with a positive or negative response to head-up tilt test. Pacing Clin Electrophysiol. 2002;25:816-821.
11. Sheldon R, Killam S. Methodology of isoproterenol-tilt table testing in patients with syncope. J Am Coll Cardiol. 1992;19:773-779.
12. Dendi R, Goldstein DS. Meta-analysis of nonselective versus beta-1 adrenoceptor-selective blockade in prevention of tilt-induced neurocardiogenic syncope. Am J Cardiol. 2002;89:1319-1321.
13. Natale A, Newby KH, Dhala A, Akhtar M, Sra J. Response to beta blockers in patients with neurocardiogenic syncope: how to predict beneficial effects. J Cardiovasc Electrophysiol. 1996;7:1154-1158.
14. Leor J, Rotstein Z, Vered Z, Kaplinsky E, Truman S, Eldar M. Absence of tachycardia during tilt test predicts failure of beta-blocker therapy in patients with neurocardiogenic syncope. Am Heart J. 1994;127:1539-1543.
15. Sheldon R, Rose S, Flanagan P, Koshman ML, Killam S. Risk factors for syncope recurrence after a positive tilt-table test in patients with syncope. Circulation. 1996;93:973-981.
16. Sheldon R, Rose S, Koshman ML. Comparison of patients with syncope of unknown cause having negative or positive tilt-table tests. Am J Cardiol. 1997;80:581-585.
17. Sheldon R, Rose S, Connolly S. Prevention of Syncope Trial (POST): a randomized clinical trial of beta blockers in the prevention of vasovagal syncope; rationale and study design. Europace. 2003;5:71-75.
18. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG; Consolidated Standards of Reporting Trials Group. CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol. 2010;63:e1-37.
19. Grambsch PM, Themeau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515-526.
20. Kaufmann H, Saadia D, Voustianiouk A. Midodrine in neurally mediated syncope: a double-blind, randomized, crossover study. Ann Neurol. 2002;52:342-345.
21. Qingyou Z, Junbao D, Chaoshu T. The efficacy of midodrine hydrochloride in the treatment of children with vasovagal syncope. J Pediatr. 2006;149:777-780.
22. Ward CR, Gray JC, Gilroy JJ, Kenny RA. Midodrine: a role in the management of neurocardiogenic syncope. Heart. 1998;79:45-49.
23. Raj SR, Faris PD, McRae M, Sheldon RS. Rationale for the prevention of syncope trial IV: assessment of midodrine. Clin Auton Res. May 19, 2012. doi: 10.1007/s10286-012-0167-5. http://www.springerlink.com/content/258j89136u11q707/ . Accessed October 2, 2012.
24. Raj SR, Rose S, Ritchie D, Sheldon RS; POST II Investigators. The Second Prevention of Syncope Trial (POST II)-a randomized clinical trial of fludrocortisone for the prevention of neurally mediated syncope: rationale and study design. Am Heart J. 2006;151:1186.e11-1186.e17.
25. Brignole M, Menozzi C, Moya A, Andresen D, Blanc JJ, Krahn AD, Wieling W, Beiras X, Deharo JC, Russo V, Tomaino M, Sutton R; International Study on Syncope of Uncertain Etiology 3 (ISSUE-3) Investigators. Pacemaker therapy in patients with neurally mediated syncope and documented asystole: Third International Study on Syncope of Uncertain Etiology (ISSUE-3): a randomized trial. Circulation. 2012;125:2566-2571.
26. Folino AF, Migliore F, Marinelli A, Iliceto S, Buja G. Age-related hemodynamic changes during vasovagal syncope. Auton Neurosci. 2010;156:131-137.
27. Sheldon R, Sexton E, Koshman ML. Usefulness of clinical factors in predicting outcomes of passive tilt tests in patients with syncope. Am J Cardiol. 2000;85:360-364.
28. Marín J. Age-related changes in vascular responses: a review. Mech Ageing Dev. 1995;79:71-114.
29. Werstiuk ES, Lee RM. Vascular beta-adrenoceptor function in hypertension and in ageing. Can J Physiol Pharmacol. 2000;78:433-452.
30. Delépine S, Prunier F, Lefthériotis G, Dupuis J, Vielle B, Geslin P, Victor J. Comparison between isoproterenol and nitroglycerin sensitized head-upright tilt in patients with unexplained syncope and negative or positive passive head-up tilt response. Am J Cardiol. 2002;90:488-491.
31. Ermis C, Samniah N, Sakaguchi S, Lurie KG, Pham S, Lu F, Benditt DG. Comparison of catecholamine response during tilt-table-induced vasovagal syncope in patients <35 to those >65 years of age. Am J Cardiol. 2004;93:225-227.
32. Sheldon R. Effects of aging on responses to isoproterenol tilt-table testing in patients with syncope. Am J Cardiol. 1994;74:459-463.
33. Sheldon RS, Sheldon AG, Connolly SJ, Morillo CA, Klingenheben T, Krahn AD, Koshman ML, Ritchie D; Investigators of the Syncope Symptom Study and the Prevention of Syncope Trial. Age of first faint in patients with vasovagal syncope. J Cardiovasc Electrophysiol. 2006;17:49-54.
34. Shigemi K, Brunner MJ, Shoukas AA. Alpha- and beta-adrenergic mechanisms in the control of vascular capacitance by the carotid sinus baroreflex system. Am J Physiol. 1994;267:H201-H210.
35. Olsen H, Vernersson E, Länne T. Cardiovascular response to acute hypovolemia in relation to age. Implications for orthostasis and hemorrhage. Am J Physiol Heart Circ Physiol. 2000;278:H222-H232.
36. Verheyden B, Liu J, van Dijk N, Westerhof BE, Reybrouck T, Aubert AE, Wieling W. Steep fall in cardiac output is main determinant of hypotension during drug-free and nitroglycerine-induced orthostatic vasovagal syncope. Heart Rhythm. 2008;5:1695-1701.
37. Theodorakis GN, Markianos M, Zarvalis E, Livanis EG, Flevari P, Kremastinos DT. Provocation of neurocardiogenic syncope by clomipramine administration during the head-up tilt test in vasovagal syndrome. J Am Coll Cardiol. 2000;36:174-178.
38. Kaizar EE. Estimating treatment effect via simple cross design synthesis. Stat Med. 2011;30:2986-3009.
39. Kunz R. Randomized trials and observational studies: still mostly similar results, still crucial differences. J Clin Epidemiol. 2008;61:207-208.
40. Shrier I, Boivin JF, Steele RJ, Platt RW, Furlan A, Kakuma R, Brophy J, Rossignol M. Should meta-analyses of interventions include observational studies in addition to randomized controlled trials? A critical examination of underlying principles. Am J Epidemiol. 2007;166:1203-1209.
41. Mak A, Cheung MW, Ho RC, Cheak AA, Lau CS. Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies. BMC Musculoskelet Disord. 2009;10:113.
42. Golder S, Loke YK, Bland M. Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview. PLoS Med. 2011;8:e1001026.
43. Moya A, Sutton R, Ammirati F, Blanc JJ, Brignole M, Dahm JB, Deharo JC, Gajek J, Gjesdal K, Krahn A, Massin M, Pepi M, Pezawas T, Ruiz Granell R, Sarasin F, Ungar A, van Dijk JG, Walma EP, Wieling W; Task Force for the Diagnosis and Management of Syncope; European Society of Cardiology (ESC); European Heart Rhythm Association (EHRA); Heart Failure Association (HFA); Heart Rhythm Society (HRS). Guidelines for the diagnosis and management of syncope (version 2009). Eur Heart J. 2009;30:2631-2671.
44. Sheldon R, Rose S, Connolly S, Ritchie D, Koshman ML, Frenneaux M. Diagnostic criteria for vasovagal syncope based on a quantitative history. Eur Heart J. 2006;27:344-350.